视网膜母细胞瘤
医学
剜除术
外科
生物化学
基因
化学
作者
R. F. Jones,Douglas J. Rhee
出处
期刊:Current Opinion in Ophthalmology
[Ovid Technologies (Wolters Kluwer)]
日期:2006-06-01
卷期号:17 (3): 228-234
被引量:322
标识
DOI:10.1097/01.icu.0000193079.55240.18
摘要
Purpose of review The current classification and management strategies for retinoblastoma are discussed. Recent findings The International Classification of Retinoblastoma is a new classification system for retinoblastoma and is based on tumor size, location, and associated seeding: group A = retinoblastoma up to 3 mm in size; group B = retinoblastoma more than 3 mm in size, macular location, or minor subretinal fluid; group C = retinoblastoma with localized seeds; group D = retinoblastoma with diffuse seeds; and group E = massive retinoblastoma necessitating enucleation. This classification was designed to simplify grouping and to assist in predicting treatment outcomes. Chemoreduction is an important therapy for bilateral retinoblastoma and some cases of unilateral retinoblastoma. This International Classification of Retinoblastoma can reliably predict chemoreduction outcome, as success was achieved in 100% of group A, 93% of group B, 90% of group C, and 47% of group D cases. Group E is typically managed with enucleation. Summary The new classification of retinoblastoma allows better judgement for success with chemoreduction for retinoblastoma.
科研通智能强力驱动
Strongly Powered by AbleSci AI